Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.36 |
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 6/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL600247 | 1.00 | RAB9A (0.36) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL694715 | 0.80 | RAB9A (0.40) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL399673 | 0.74 | ALDH1A1 (0.49) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL694716 | 0.72 | RAB9A (0.45) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL694714 | 0.72 | RAB9A (0.45) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL10039876 | 0.69 | RAB9A (0.55) | RAB9ANPC1ARCYP3A4CYP1A2 | |
| SCHEMBL1492173 | 0.69 | LMNA (0.50) | CYP1A2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL13489309 | 0.69 | LMNA (0.50) | CYP1A2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL1493603 | 0.69 | LMNA (0.50) | CYP1A2MEN1KMT2AALDH1A1MAPT | |
| SCHEMBL26675645 | 0.68 | DHODH (0.48) | RAB9ANPC1ARCYP3A4CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| US-8513415-B2 | Preparation of C-pyrazine-methylamines | OSI Pharmaceuticals, LLC (US) | 2013-08-20 | — | — | US | disclosed |
| EP-2421837-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI Pharmaceuticals, LLC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | OSI Pharmaceuticals, LLC | 2012-02-16 | — | — | US | disclosed |
| WO-2010123792-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010123792-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | OSI PHARMACEUTICALS, INC. (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261306-A1 | PREPARATION OF C-PYRAZINE-METHYLAMINES | DOT1L, INMT, H1-5 | RAB9A 1394/4885NPC1 2245/4885AR 1184/4885 |
| US-20120041202-A1 | Preparation of C-Pyrazine-Methylamines | DOT1L, INMT, H1-5 | RAB9A 1394/4885NPC1 2245/4885AR 1184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.